Simvastatin in vitiligo: an update with recent review of the literature

Rashidul Hasan, Komal Agarwal, Indrashis Podder, Angelica Misitzis, Robert A. Schwartz, Uwe Wollina, Torello Lotti, Stephan Grabbe, Mohamad Goldust

Research output: Contribution to journalReview articlepeer-review


Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.

Original languageAmerican English
Pages (from-to)e390-e396
JournalInternational journal of dermatology
Issue number10
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Simvastatin in vitiligo: an update with recent review of the literature'. Together they form a unique fingerprint.

Cite this